- Home
- NLOP vs CSTL Comparison
NLOP vs CSTL Comparison
Compare NLOP & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- CSTL
- Stock Information
- Founded
- NLOP N/A
- CSTL 2007
- Country
- NLOP United States
- CSTL United States
- Employees
- NLOP N/A
- CSTL N/A
- Industry
- NLOP
- CSTL Medical Specialities
- Sector
- NLOP
- CSTL Health Care
- Exchange
- NLOP Nasdaq
- CSTL Nasdaq
- Market Cap
- NLOP 498.8M
- CSTL 561.9M
- IPO Year
- NLOP N/A
- CSTL 2019
- Fundamental
- Price
- NLOP $33.47
- CSTL $16.07
- Analyst Decision
- NLOP Strong Buy
- CSTL Strong Buy
- Analyst Count
- NLOP 1
- CSTL 6
- Target Price
- NLOP $46.00
- CSTL $37.67
- AVG Volume (30 Days)
- NLOP 56.0K
- CSTL 410.9K
- Earning Date
- NLOP 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- NLOP 1.02%
- CSTL N/A
- EPS Growth
- NLOP N/A
- CSTL N/A
- EPS
- NLOP N/A
- CSTL N/A
- Revenue
- NLOP $127,453,000.00
- CSTL $347,083,000.00
- Revenue This Year
- NLOP N/A
- CSTL N/A
- Revenue Next Year
- NLOP N/A
- CSTL $1.36
- P/E Ratio
- NLOP N/A
- CSTL N/A
- Revenue Growth
- NLOP N/A
- CSTL 38.43
- 52 Week Low
- NLOP $26.10
- CSTL $15.45
- 52 Week High
- NLOP $34.53
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- NLOP 56.95
- CSTL 31.25
- Support Level
- NLOP $32.80
- CSTL $16.16
- Resistance Level
- NLOP $33.61
- CSTL $17.31
- Average True Range (ATR)
- NLOP 0.60
- CSTL 0.79
- MACD
- NLOP -0.05
- CSTL -0.40
- Stochastic Oscillator
- NLOP 54.70
- CSTL 1.64
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.